NCT03819387已完成1 期
A Phase I/Ib Open-Label, Multi-Center, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics and Preliminary Efficacy of Intravenous NBF 006 in Patients With Non-Small Cell Lung, Pancreatic, or Colorectal Cancer Followed by a Dose Expansion Study in Patients With KRAS-Mutated Non-Small Cell Lung Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 49
- 试验地点
- 9
- 主要终点
- Number of patients with treatment-related adverse events as assessed by CTCAE v5.0
研究概览
简要总结
This is an open-label, non-controlled study conducted in two parts - Part A (dose escalation) followed by Part B (dose expansion).
详细描述
Patients in Part A will have previously treated progressive or metastatic NSCLC, pancreatic, or colorectal cancer, with or without KRAS mutation. Five dose levels will be explored. In dose level 5, only patients with previously-treated NSCLC with KRAS mutation will be included.
Patients in Part B must have previously treated NSCLC with confirmed KRAS mutation. Two dose levels will be explored further in Part B. Twenty (20) patients will be enrolled in Part B, with 10 patients enrolled in each of the two cohorts. Once dose level 5 has been confirmed to be safe in Part A (i.e. 0-1 DLT in 6 patients), an additional 4 patients will then be enrolled for a planned total of 24 patients in Part B.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Part A: Patients with histologically or cytologically confirmed progressive or metastatic NSCLC, pancreatic, or colorectal cancer that have failed standard treatment and for which no other effective treatment is available or appropriate for the patient up to dose level
- •In dose level 5, patients with histologically or cytologically confirmed progressive or metastatic NSCLC with documented KRAS-mutant genotype, who have failed standard treatment and have no other effective treatment available or appropriate for the patient.
- •Part B: Patients with histologically or cytologically confirmed progressive or metastatic NSCLC with documented KRAS-mutant genotype, who have failed standard treatment and have no other effective treatment available or appropriate for the patient.
- •Eastern Cooperative Oncology Group performance status of 0-
- •Men and women ≥ 18 years of age.
- •Patients must have recovered from all acute adverse effects (excluding alopecia) of prior therapies to baseline or ≤ Grade 1 prior to study entry.
- •Adequate bone marrow function, defined as an absolute neutrophil count (ANC) ≥ 1.5 x 109/L and a platelet count ≥ 100 x 109/L.
- •Adequate renal function, defined as serum creatinine ≤ 1.5 x upper limit of normal (ULN) for the institution or calculated creatinine clearance [Cockcroft-Gault method] must be ≥ 60 mL/min/1.73 m². If serum creatinine is >1.5 x ULN, then creatinine clearance can be calculated from a 24-hour urine collection.
- •Adequate hepatic function, defined as total bilirubin ≤ 1.5 mg/dL and alanine transaminase (ALT) and aspartate transaminase (AST) ≤ 2.5 x ULN, or ≤ 5 x ULN if known liver metastases.
- •Female patients of childbearing potential must have a negative serum or urine pregnancy test result at time of pre-treatment screening.
- •Patients with reproductive potential must agree to use at least one form of highly effective contraception prior to study entry and for up to 30 days beyond the last administration of study drug.
- •Patients must be capable of providing informed consent and must be willing to provide written informed consent prior to the start of any study-specific procedures.
- •All patients must have measurable tumor per RECIST 1.
- •Agree to adhere to all study protocol requirements.
排除标准
- •Prior chemotherapy, radiation therapy, or investigational therapy within 4 weeks (exception: 6 weeks for nitrosoureas or mitomycin C); or prior non-cytotoxic therapy within 5 drug half-lives (or 4 weeks, whichever is shorter); or monoclonal antibodies within 4 weeks prior to the first dose of study treatment.
- •Concurrent use of any other investigational agent.
- •Known or clinically suspected central nervous system or leptomeningeal metastases, unless irradiated or treated a minimum of 4 weeks prior to first study treatment and stable without requirement of corticosteroids for > 1 week.
- •Pregnant or breast feeding. A negative pregnancy test must be documented at baseline for women of childbearing potential. Patients may not breast-feed infants while on this study.
- •Significant cardiovascular disease or condition, including:
- •Congestive heart failure currently requiring therapy
- •Need for antiarrhythmic medical therapy for ventricular arrhythmia
- •Severe conduction disturbance
- •Angina pectoris requiring therapy
- •QTc interval > 450 msec (males) or > 470 msec (females) Fridericia's correction.
- •Note: QTc values up to 500 ms will be acceptable where patient's medical history e.g. bundle branch block, is known to cause mild QTc prolongation and the condition is well controlled.
- •History of congenital long QT syndrome or congenital short QT syndrome
- •Uncontrolled hypertension (per the Investigator's discretion)
- •Class III or IV cardiovascular disease according to the New York Heart Association's Functional Criteria
- •Myocardial infarction within 6 months prior to first study drug administration
- •Known history of human immunodeficiency virus or active infection with hepatitis B virus or hepatitis C virus.
- •Known uncontrolled intercurrent illnesses, including uncontrolled viral influenza and COVID 19, systemic bacterial infections, and fungal infections.
- •Psychiatric disorder or altered mental status that would preclude understanding of the informed consent process and/or completion of the necessary studies.
- •Known allergic reactions to H1/H2 antagonists.
研究组 & 干预措施
NBF-006
Experimental
干预措施: NBF-006 (Drug)
结局指标
主要结局
Number of patients with treatment-related adverse events as assessed by CTCAE v5.0
时间窗: Change in the incidence and severity of adverse events related to study treatment from baseline to 4 weeks following last dose
次要结局
- Pharmacokinetic parameters for siRNA(Up to 72 hours from start of infusion on Cycle 1, Day 1 and Day 22 and prior to infusion Cycle 1, Day 8 and Cycle 2, Day 1)
- Best Overall Response per RECIST 1.1(Number of days from date of first dose to 30 days after last treatment)
- Additional pharmacokinetic parameters for siRNA(Up to 72 hours from start of infusion on Cycle 1, Day 1 and Day 22 and prior to infusion Cycle 1, Day 8 and Cycle 2, Day 1)
研究者
研究点 (9)
Loading locations...
相似试验
终止
1 期
A Dose Escalation Study in Solid Tumors and a Dose Expansion Study of PRN1371 in Adult Patients With Metastatic Urothelial CarcinomaSolid TumorsMetastatic Urothelial Carcinoma & Renal Pelvis & UreterNCT02608125Principia Biopharma, a Sanofi Company45
已完成
1 期
A Two Part Study of RO6870810. Dose-Escalation Study in Participants With Advanced Solid Tumors and Expansion Study in Participants With Selected MalignanciesSolid Tumors, Advanced Solid TumorsNCT01987362Hoffmann-La Roche52
已完成
1 期
Evaluate Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of AZD3759Non Small Cell Lung CancerNCT03360929LYZZ Alpha Holding Ltd15
已完成
1 期
Clinical Study of CMP-001 in Combination With Pembrolizumab or as a MonotherapyMelanomaNCT02680184Regeneron Pharmaceuticals199
招募中
1 期
Phase 1/2 Study of HYP-2090PTSA in Patients With Advanced Solid Tumors Harboring KRAS MutationSafetyTolerabilityEfficacyNCT06243354Sichuan Huiyu Pharmaceutical Co., Ltd257